Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sartorius Stedim Biotech : Close to a key resistance level

07/06/2021 | 02:47am EST
long trade
Target price hit
Entry price : 408.4€ | Target : 500€ | Stop-loss : 335€ | Potential : 22.43%
Sartorius Stedim Biotech is close to a major resistance level, whereby the breach of this level could be considered as a buy signal. This reflects our preferred scenario in light of the stock's current technical chart pattern.
Investors have an opportunity to buy the stock and target the € 500.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : Close to a key resistance level
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company returns high margins, thereby supporting business profitability.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.

Weaknesses
  • With an expected P/E ratio at 73.34 and 65.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company is not the most generous with respect to shareholders' compensation.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 2 874 M 3 261 M 3 261 M
Net income 2021 595 M 675 M 675 M
Net Debt 2021 538 M 611 M 611 M
P/E ratio 2021 59,1x
Yield 2021 0,37%
Capitalization 34 752 M 39 415 M 39 430 M
EV / Sales 2021 12,3x
EV / Sales 2022 10,5x
Nbr of Employees 9 619
Free-Float -
Upcoming event on SARTORIUS STEDIM BIOTECH
01/27/22
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 377,00 €
Average target price 471,11 €
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chairman & Chief Executive Officer
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Susan Dexter Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SARTORIUS STEDIM BIOTECH-21.85%40 085
ABBOTT LABORATORIES-11.39%213 874
MEDTRONIC PLC2.57%142 671
BECTON, DICKINSON AND COMPANY4.93%75 243
HOYA CORPORATION-10.96%49 292
BAXTER INTERNATIONAL INC.0.17%43 055